مدخل الى التوصيات والمقترحات والوسائل لإصلاح النظام الصحي في العراق من زاوية التسويق الدوائي

المصادر:

1.                    Lexchin, J. (2017). The Pharmaceutical Industry and the Canadian Government: Folie à Deux. Healthcare Policy, 13(1), 10-16. https://doi.org/10.12927/hcpol.2017.25195

2.                    't Hoen E., 2016. Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines. Amsterdam, NL: HAI. 

3.                    Lexchin J. 2016. “How Safe and Innovative are First in Class Drugs Approved by Health Canada: A Cohort Study.” Healthcare Policy 12(2)6: 65–75. 10.12927/hcpol.2016.24851. 

4.                    Fojo T., Mailankody S., Lo A. 2014. “Unintended Consequences of Expensive Cancer Therapeutics – The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. The John Conley Lecture.” JAMA Otolaryngology Head and Neck Surgery 140: 1225–36.

5.                    https://tec-moh.com/?page_id=6393

6.                    https://tec-moh.com/?p=6321

7.                    https://wiki.dorar-aliraq.net/iraqilaws/law/8588.html#google_vignette

8.                    Mueller C (1997). "Prescription Drug Spending: The Impact of Age and Chronic Disease Status". American Journal of Public Health 10: 1626–29.

9.                    Mold RJG; Ekins S .Time for cooperation in health economics among the modeling community, PharmacoEconomics, 28(8):609-613, 2010.

10.                Tonin, F. S. et al, (2021). Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharmacy Practice, 19(1).

11.                https://doi.org/10.18549/PharmPract.2021.1.2302

12.                https://www.appliedclinicaltrialsonline.com/view/pharmacovigilance-vs-drug-safety

13.                https://moh.gov.iq/?page=40

14.                Institute for Safe Medication Practices. Home Page. http://www.ismp.org Accessed 12 Jan 2015.

15.                Allen J. Vaida .The Institute for Safe Medication Practices and Poison Control Centers: Collaborating to Prevent Medication Errors and Unintentional Poisonings. J Med Toxicol. 2015 Jun; 11(2): 262–264.

16.                The Institute for Safe Medication Practices Canada. https://ismpcanada.ca/

17.                https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

18.                https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/networks/pidm

19.                https://who-umc.org/vigibase/

20.                https://who-umc.org/pv-products/vigiflow/

21.                Cristianisme I Justícia. Crimes and abuses of the pharmaceutical industry. https://www.cristianismeijusticia.net › files › pdf

22.                https://www.ojp.gov/taxonomy/term/pharmacy-crimes

23.                Activity report of the commission for control of Interpol files for 2018. C.C.F.-BP 6041-69411 Lyon Cedex 06-France-e-mail: CCF@interpol.Int

24.                https://www.interpol.int/News-and-Events/News/2023/Global-illicit-medicines-targeted-by-INTERPOL-operation

25.                Delivering quality health services: a global imperative for universal health coverage [ ISBN 978-92-4-651390-1 World Health Organization (WHO) https://iris.who.int › handle › 9789246513901-ara

26.                Sustainable development goals› https://sdgs.un.org 

27.                https://www.ema.europa.eu/en/homepage

28.                Paschke Anne, et al.Increasing transparency and accountability in national pharmaceutical systems. Bull World Health Organ. 2018 Nov 1; 96(11): 782–791.

29.                Pharmaceutical Inspection Co-operation Scheme (PIC/S). https://picscheme.org/en/about

30.                 Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993; 329(8):573–576.

31.                Lo and Field (2009). The definition originally appeared in Thompson (1993).

32.                WHO. Ethical criteria for medicinal drug promotion. Geneva: World Health Organization; 1988.

33.                Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283:373- 380.

34.                Weinstein S .Conflict of interest at work | definition, types & examples. https://study.com/academy/lesson/conflicts-of-interest-in-the-workplace.html

35.                Rochon PA, et al. Financial Conflicts of Interest Checklist (FCIC) for investigator (s). Medicine, Vol 4, No 1 (2010)

36.                Progress Report on Financial and Conflicts of Interest Disclosure Systems at World Intellectual Property Organization (WIPO). https://www.wipo.int

37.                https://wiki.dorar-aliraq.net/iraqilaws/law/3081.html

38.                https://wiki.dorar-aliraq.net/iraqilaws/law/6952.html#google_vignette

39.                http://site.eastlaws.com/GeneralSearch/Home/ArticlesTDetails?MasterID=1808489

40.                https://wiki.dorar-aliraq.net/iraqilaws/law/10348.html#google_vignette

41.                https://www.who.int/ar/news/item/08-02-1445-new-who-civil-society-commission-to-strengthen-civil-society-organizations--role-in-accelerating-progress-in-global-health

42.                Fidler, David P. "From international sanitary conventions to global health security: the new International Health Regulations." Chinese Journal of International Law 4.2 (2005): 325-392.

43.                https://academic.oup.com/chinesejil/article/4/2/325/490058

44.                https://www.who.int/ar/news/item/08-02-1445-new-who-civil-society-commission-to-strengthen-civil-society-organizations--role-in-accelerating-progress-in-global-health